CymaBay Therapeutics (CBAY) Reports In-Line Q4 EPS

CymaBay Therapeutics (NASDAQ: CBAY) reported Q4 EPS of ($0.30), in-line with the analyst estimate of ($0.30). Revenue for the quarter came in at $0 versus the consensus estimate of $5 million.

For earnings history and earnings-related data on CymaBay Therapeutics (CBAY) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Jernigan Capital (JCAP) Tops Q2 EPS by 5c
• Lument Finance Trust (LFT) Misses Q2 EPS by 17c